公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y. | The Lancet Oncology | 722 | 630 | |
2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | Okada M.; Kato K.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Matsumura Y.; Takazawa A.; Kitagawa Y. | Clinical Cancer Research | 18 | 16 |